CN102294019A - Application of cathelicidin-BF - Google Patents
Application of cathelicidin-BF Download PDFInfo
- Publication number
- CN102294019A CN102294019A CN2011102650119A CN201110265011A CN102294019A CN 102294019 A CN102294019 A CN 102294019A CN 2011102650119 A CN2011102650119 A CN 2011102650119A CN 201110265011 A CN201110265011 A CN 201110265011A CN 102294019 A CN102294019 A CN 102294019A
- Authority
- CN
- China
- Prior art keywords
- cathelicidin
- staphylococcus aureus
- escherichia coli
- medicine
- bacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention belongs to the technical field of biomedicine, and in particular relates to application of cathelicidin-BF in the preparation of a medicine for treating bacterial vaginosis. The cathelicidin-BF has the advantages of good bactericidal effects on staphylococcus aureus and escherichia coli in vitro and high sterilization speed; the effect of the cathelicidin-BF on the vaginosis infected by the escherichia coli is the same as the result of the cathelicidin-BF in the vaginosis infected by the staphylococcus aureus basically; and the cathelicidin-BF can obviously restrain the staphylococcus aureus or the escherichia coli in vagina, has an obvious effect of reducing inflammation and can be applied in the preparation of the medicine for treating the bacterial vaginosis.
Description
Technical field:
The invention belongs to field of biomedicine technology, be specifically related to the application of Bungarus fasciatus antibacterial peptide cathelicidin-BF in preparation treatment bacterial vaginitis medicine.
Background technology:
Cathelicidin is one and has multi-functional antibacterial peptide family, only in mammals, birds and Fish discovery arranged at present.Cathelicidin has broad-spectrum antibacterial activity, not only gram positive bacteria, gram negative bacteria, some fungus and virus is had very strong bactericidal activity, and many clinical drug-resistant antibacterials are had effect equally.In addition, cathelicidin also has many other biologicals and learns activity, as the panimmunity cell being had chemotaxis, inducing mastocyte threshing and histamine's release, adjusting macrophage to transcribe, promote wound healing, induction of vascular generation, induce variation cell line cell apoptosis and lymphocyte activation etc.Because have so numerous activity, cathelicidin is the focus of studying in the world always.Then containing huge clinical treatment medication preparation at the medicinal exploitation of cathelicidin is worth.
Along with antibiotic extensive and incorrect uses of tradition such as penicillins, microorganism has produced more and more stronger toleration to traditional antibiotic, occurred can tolerating fully in a large number traditional antibiotic microorganisms such as penicillin clinically, existing antibiotic is powerless to these pathogenic microorganisms.Antibacterial peptide is a kind of novel antimicrobial polypeptide, and most of antibacterial peptide molecular weight are less than 10000Da, and positively charged is rich in hydrophobic base, can form amphipathic structure.The bactericidal mechanism of antibacterial peptide mainly is by electrostatic interaction attraction and is attached to electronegative bacterial cell membrane surface, further forms the hole of striding film on bacterial cell membrane, causes leaking of bacterial cell content, thereby causes the death of bacterial cell.And traditional antibiotic mainly is some enzymes that act in the bacterial cell.Just because of the difference of model of action, the bactericidal action of antibacterial peptide mediation is far away faster than traditional antibiotic, and is difficult for making antibacterial to produce toleration.In addition, increasing bibliographical information shows that antibacterial peptide also has other bactericidal mechanism, as suppress bacteria cell wall synthetic, change the bacterial cell plasma membrane and suppress barrier film and form, activate autolysin, suppress the desmoenzyme activity, suppress DNA, RNA and proteinic synthetic etc.
At present, have many companies carrying out the research and development of antibacterial peptide abroad, existing multiple antibacterial peptide enters clinical experimental stage.As the hLF-1-1 that derives from people lactoferrin is used for the treatment of the relevant infection of Bone Marrow Stem Cells Transplantation, entered the clinical II phase.The MSI-78 that derives from Africa xenopus magainin has significant curative effect and side effect little to the foot ulcers of diabetics, has entered clinical III phase experimental stage.The IB-367 that derives from pig protegrin is used for the treatment of the tumor patient oral ulcer, has entered the clinical I phase to test.In addition, some are used for wound healing, and endotoxin infects, tumor, and the antibacterial peptide of viral infection has also entered clinical experimental stage.
In the Chinese medicine and national medicine of China, many Serpentis classes are used as medical material and are widely used, as black-snake, and Boa Serpentis, Agkistrodon halys, Bungarus fasciatus, Agkistrodon, Naja, Agkistrodon etc.The Serpentis whole body all can be used as medicine, and Carnis Serpentis has strong nerve, life lengthening effect, can treat weak after being ill, diseases such as migratory arthralgia is numb, arthralgia.Fel Serpentis have dispel the wind, heat clearing away, the effect of reducing phlegm, making eye bright, cure mainly infantile malnutrition, swelling and pain of hemorrhoid.The Fel Serpentis alcoholic solution can effectively be treated keratitis, corneal ulcer, corneal macula.With Fel Serpentis, Bulbus Fritillariae Cirrhosae, Semen Armeniacae Amarum is " Fel Serpentis et Bulbus Fritillariae Cirrhosae Liquidus " that primary raw material is made, be present clinical eliminating phlegm and stopping cough good medicine easy to use, evident in efficacy, Periostracum Serpentis has the function of expelling wind for relieving convulsion, parasite killing, nebula removing detumescence, heat-clearing and toxic substances removing, can control diseases such as corneal nebula, furuncle, anal fistula, mumps, malaria, pediatric epilepsy scared, scabies, scrofula.Snake venom is a very expensive rare medical material on the present international medical material market, and the injection that utilizes agkistrodon halyx pallas venom to make has significantly anticancer, anticoagulant effect.
Meanwhile, the complexity of Chinese medicine ingredient and the limitation of concocting method thereof cause active constituents of medicine can better not play a role, thereby the specific activated monomer chemical compound of searching is one of important content of the modernization of Chinese medicine from these conventional medicaments.Up to now, Chinese scholars has been isolated large number of biological activated protein and polypeptide from snake venom, and many active polypeptide wherein have good drug development prospect.
Bungarus fasciatus antibacterial peptide cathelicidin-BF by the inventor from the Bungarus fasciatus venom find by 30 aminoacid form antimicrobial peptide, contain 30 amino acid residues, molecular weight is 3637.54Da, isoelectric point, IP 11.79.Bungarus fasciatus antibacterial peptide cathelicidin-BF total order is classified as: lysine-phenylalanine-phenylalanine-arginine-lysine-leucine-lysine-lysine-serine-valine-lysine-lysine-arginine-alanine-LYS-GLU-phenylalanine-phenylalanine-lysine-Lys-Pro-arginine-valine-isoleucine-glycine-valine-serine-isoleucine-proline-phenylalanine, has significant antibacterial activity, and hemolytic activity and cytotoxicity are all very low (sees document Wang Y, Hong J, Liu X, Yang H, Liu R, Wu J, Wang A, Lin D, Lai R.Snake cathel icidin from Bungarus fasciatusis a potent peptide antibiotics.PLoS One.2008; 3 (9): e3217).
The inventor as the application in the preparation treatment bacterial vaginitis medicine, finds no any same application with Bungarus fasciatus antibacterial peptide cathelicidin-BF.
Summary of the invention:
The object of the present invention is to provide the application of a kind of Bungarus fasciatus antibacterial peptide cathelicidin-BF in preparation treatment bacterial vaginitis medicine.
In order to realize purpose of the present invention, the invention provides following technical scheme:
Investigate the sensitivity of two kinds of common bacterial vaginitis pathogen (staphylococcus aureus and escherichia coli) to cathelicidin-BF
Adopt agar plate dilution method to measure the minimal inhibitory concentration (MIC) of cathelicidin-BF to antibacterial.Get 12 of sterile test tube (10ml), be arranged in a row.Every pipe adds sterilized water 1ml, at the 1st pipe adding medicine stock solution (1280 μ g/ml) 1ml mixing, draws 1ml to the 2 pipes then, draws 1ml to the 3 behind the mixing again and manages, and doubling dilution to the 12 is managed so continuously, abundant mixing before every dilution.Respectively manage drug level and be followed successively by 640,320,160,80,40,20,10,5,2.5,1.25,0.625,0.313 μ g/ml this moment.Solution with each concentration adds in the plate then, and the 1ml/ ware adds the MH agar culture medium of 9ml again, and the limit edged shakes, and makes it abundant mixing.This moment, each plate drug level was respectively 64,32,16,8,4,2,1,0.5,0.25,0.125,0.0625,0.0313 μ g/ml.Simultaneously, establish blank and negative control.With the inoculum for preparing, add 96 orifice plates, 250 μ l/ holes are inoculated with sample applicator.The plate that inoculation is good is inverted, and hatches 16h in 37 ℃ of normal air incubators.Whether the bacterial growth situation of checking blank is good, and with perusal, medicine least concentration group does not have bacterial growth person is the MIC that is tried bacterium.
Investigate extracorporeal disinfecting speed
Adopt 4 times to the drug level of MIC, with prepare 1～2 * 10
6The bacteria suspension of CFU/ml and medicament mixed, making its concentration is 10
5About CFU/ml.0,1,2,4,6,8,10,12 with during 24h, draw culture, carry out serial dilution, count plate, each dilution factor are done three parallel laboratory tests, average.Be vertical coordinate with the bacterial concentration logarithm at last, incubation time is an abscissa, draws killing curve.
Investigation is to the therapeutical effect of rat bacterial vaginitis
The foundation of bacterial vaginitis model
At first embrocate the rat vagina inwall repeatedly 15 times, make the vaginal mucosa mechanical injuries, cause cotton swab to be stained with a little courageous and upright mucus and be degree, inject the bacterium liquid (about 10 of escherichia coli or staphylococcus aureus then to rat vagina with aseptic harder cotton swab
9CFU/ml), injection bacterium liquid measure is 50 μ l/200g, injects the position apart from vaginal orifice 5mm, and inoculate once every day, inoculates altogether 7 times, observes the rat vagina mucosa every day, gets vaginal secretions in the 9th day after inoculating the first day to carry out microscopy and antibacterial culturing, and makes identification of strains.It is positive that pathogen is checked, and the perusal vaginal mucosa hyperemia, edema, hemorrhage or infiltration person is all taken place for to infect successfully.Successful rat random packet treatment will be infected.
Grouping of animal and administration
The SD rat that success is infected is divided into 5 groups at random, 10/group.The group of treatment bacterial vaginitis model be respectively high (0.8mg/kg), in (0.4mg/kg), low (0.2mg/kg) dosage group, positive control (ciprofloxacin 0.5mg/kg) and model group (giving the normal saline of same volume).Each organizes rat vagina administration every day once, BF-30 is made into the solution of variable concentrations with normal saline, and cathelicidin-BF, positive controls and the model group of injecting 50 μ l variable concentrations by outer intravaginal 5mm place with the syringe of 200 μ l gives the ciprofloxacin and the normal saline of equal volume respectively.
Organize colony counting and tissue slice
Successive administration 7 days is got rat vagina secretions and is checked after the drug withdrawal, observe vaginal mucosa pathological changes situation and pathogen survival condition.Stretch into rat vagina 0.5cm with 2 aseptic cotton carrier rods and rotate, place in the 3ml physiological saline solution and soak, behind the mixing, carry out clump count and calculate.Put to death rat in administration after 7 days, dissect, get the about 1cm of vagina, fixing in the formaldehyde of placement 10%.Conventional fixing, the light microscopic histological observation is carried out in HE dyeing then.
Beneficial effect of the present invention is:
Chemosynthesis Bungarus fasciatus antibacterial peptide cathelicidin-BF, external to staphylococcus aureus and escherichia coli have strong bactericidal action, beneficial features rapidly sterilizes.Cathelicidin-BF is basic identical to colpitic effect and its colpitic result to infection of staphylococcus aureus of coli-infection, it obviously suppresses intravaginal staphylococcus aureus or escherichia coli, cathelicidin-BF has the effect that significantly reduces inflammation, can be as the application in the preparation treatment bacterial vaginitis medicine.
Description of drawings:
Fig. 1 is the killing curve (MIC=16 μ g/ml) of cathelicidin-BF to staphylococcus aureus (ATCC25923).
Fig. 2 is the killing curve (MIC=2 μ g/ml) of cathelicidin-BF to escherichia coli (ATCC25922).
The specific embodiment:
Further specify essentiality content of the present invention with embodiment below, but content of the present invention is not limited thereto.
One, investigates the sensitivity of two kinds of common bacterial vaginitis pathogen (staphylococcus aureus and escherichia coli) to cathelicidin-BF
1. material
1.1 bacterial strain: clinical isolated bacterial vaginitis the infected's staphylococcus aureus (11 strain) and escherichia coli (10 strain).
1.2 culture medium Nutrient agar, meat soup, Mueller-Hinton (MH) agar culture medium (antibacterial), husky fort agar culture medium.
1.3 medicine: chemosynthesis Bungarus fasciatus antibacterial peptide cathelicidin-BF, bacitracin, ciprofloxacin, ampicillin and azithromycin etc.
2 investigate the sensitivity of fastbacteria to cathelicidin-BF
Measure cathelicidin-BF to staphylococcus aureus and colibacillary MIC 2.1 adopt agar plate dilution method.Get 12 of sterile test tube (10ml), be arranged in a row.Every pipe adds sterilized water 1ml, at the 1st pipe adding medicine stock solution (1280 μ g/ml) 1ml mixing, draws 1ml to the 2 pipes then, draws 1ml to the 3 behind the mixing again and manages, and doubling dilution to the 12 is managed so continuously, abundant mixing before every dilution.Respectively manage drug level and be followed successively by 640,320,160,80,40,20,10,5,2.5,1.25,0.625,0.313 μ g/ml this moment.Solution with each concentration adds in the plate then, and the 1ml/ ware adds the MH agar culture medium of 9ml again, and the limit edged shakes, and makes it abundant mixing.This moment, each plate drug level was respectively 64,32,16,8,4,2,1,0.5,0.25,0.125,0.0625,0.0313 μ g/ml.Simultaneously, establish blank and negative control.With the inoculum for preparing, add 96 orifice plates, 250 μ l/ holes are inoculated with sample applicator.The plate that inoculation is good is inverted, and hatches 16h in 37 ℃ of normal air incubators.Whether the bacterial growth situation of checking blank is good, and with perusal, medicine least concentration group does not have bacterial growth person is the MIC that is tried bacterium.The result is as shown in table 1.
Table 1 cathelicidin-BF is to the antibacterial activity of escherichia coli and staphylococcus aureus
Annotate: ND represents there is not activity
Know that by table 1 cathelicidin-BF has stronger antibacterial activity to most test strains, especially escherichia coli are all had strong bactericidal action.
Two, investigate extracorporeal disinfecting speed
Adopt 4 times to the drug level of MIC, with prepare 1～2 * 10
6The bacteria suspension of CFU/ml and medicament mixed, making its concentration is 10
5About CFU/ml.0,1,2,4,6,8,10,12 with during 24h, draw culture, carry out serial dilution, count plate, each dilution factor are done three parallel laboratory tests, average.Be vertical coordinate with the bacterial concentration logarithm at last, incubation time is an abscissa, draws killing curve.
The result as depicted in figs. 1 and 2.Know that by Fig. 1 and Fig. 2 cathelicidin-BF has bactericidal activity fast to staphylococcus aureus and escherichia coli, especially staphylococcus aureus is all had bactericidal action fast, in 4 hours, can all kill staphylococcus aureus.
Three, investigation is to the therapeutical effect of rat bacterial vaginitis
1, experimental technique
1.1 the foundation of bacterial vaginitis model
At first embrocate the rat vagina inwall repeatedly 15 times, make the vaginal mucosa mechanical injuries, cause cotton swab to be stained with a little courageous and upright mucus and be degree, inject the bacterium liquid (about 10 of escherichia coli or staphylococcus aureus then to rat vagina with aseptic harder cotton swab
9CFU/ml), injection bacterium liquid measure is 50 μ l/200g, injects the position apart from vaginal orifice 5mm, and inoculate once every day, inoculates altogether 7 times, observes the rat vagina mucosa every day, gets vaginal secretions in the 9th day after inoculating the first day to carry out microscopy and antibacterial culturing, and makes identification of strains.It is positive that pathogen is checked, and the perusal vaginal mucosa hyperemia, edema, hemorrhage or infiltration person is all taken place for to infect successfully.Successful rat random packet treatment will be infected.
1.2 grouping of animal and administration
The SD rat that success is infected is divided into 5 groups at random, 10/group.The group of treatment bacterial vaginitis model be respectively high (0.8mg/kg), in (0.4mg/kg), low (0.2mg/kg) dosage group, positive control (ciprofloxacin 0.5mg/kg) and model group (giving the normal saline of same volume).Each organizes rat vagina administration every day once, cathelicidin-BF is made into the solution of variable concentrations with normal saline, inject the cathelicidin-BF of 50 μ l variable concentrations with the syringe of 200 μ l by outer intravaginal 5mm place, positive controls and model group give the ciprofloxacin and the normal saline of equal volume respectively.
1.3 organize colony counting and tissue slice
Successive administration 7 days is got rat vagina secretions and is checked after the drug withdrawal, observe vaginal mucosa pathological changes situation and pathogen survival condition.Stretch into rat vagina 0.5cm with 2 aseptic cotton carrier rods and rotate, place in the 3ml physiological saline solution and soak, behind the mixing, carry out clump count and calculate.Put to death rat in administration after 7 days, dissect, get the about 1cm of vagina, fixing in the formaldehyde of placement 10%.Conventional fixing, the light microscopic histological observation is carried out in HE dyeing then.
The result is as follows:
Bacterial colony count
Compare with model group (only giving normal saline every day), the cathelicidin-BF of administration every day 0.4mg/kg and 0.8mg/kg all can make the concentration of staphylococcus aureus in the rat vagina significantly reduce, can be from 10
7Be reduced to 10
3CFU/ml, and present good dose dependent.Low dose group (0.2mg/kg) does not almost have inhibitory action to staphylococcus aureus, and the bacteriostatic activity of the cathelicidin-BF of middle dosage and high dose is suitable, and its action effect is obviously good than ciprofloxacin.
Bungarus fasciatus antibacterial peptide cathelicidin-BF is basic identical to colpitic effect and its colpitic result to infection of staphylococcus aureus of coli-infection, it also has tangible dose dependent to intravaginal colibacillary inhibitory action, when dosage is 0.8mg/kg, fungistatic effect is best, can make intravaginal bacterial concentration from 10
6Be reduced to 10
4CFU/ml, the bacteriostasis of middle dosage is only second to high dose, a little less than the low dosage effect.
The vagina tissue sections observation of infection of staphylococcus aureus
Normal group:
The vaginal mucosa table is by stratified squamous epithelium, and epithelial cell does not have degeneration, necrosis, and epidermis does not have erosion, ulcer, and last subcutaneous tissue does not have hyperemia, edema, no cell infiltration.
Model group:
The vaginal mucosa histological structure is identical with normal group, and table is by stratified squamous epithelium, and epithelial cell does not have degeneration, necrosis, does not have rotten to the corn, ulcer.Mucosal epithelium undertissue does not have obvious hyperemia, edema, but has shallow-layer that slight or moderate cell infiltration are arranged, and the inflammatory cell type is mainly mononuclear phagocyte, and minority is a neutrophilic granulocyte.Mucosa undertissue does not have obvious pathological changes.
The cathelicidin-BF high dose group:
The vaginal mucosa histological structure is identical with normal group, and table is by stratified squamous epithelium, and the surface is keratinization (normal cycle sexually revises) slightly, and epithelial cell does not have degeneration, necrosis, does not have rotten to the corn, ulcer.There is slight cell infiltration in shallow layer tissue under 1 mucosal epithelium, the same model group of type.Mucosa undertissue does not have obvious pathological changes.
Dosage group among the cathelicidin-BF:
The vaginal mucosa histological structure is identical with normal group, and mucosal epithelium and mucosa undertissue do not have obvious pathological changes.
The cathelicidin-BF low dose group:
The vaginal mucosa histological structure is identical with normal group, and there is a small amount of cell infiltration in shallow layer tissue under 2 mucosal epithelium, and type is with last identical, and wherein 1 mucosa undertissue is with mild hyperaemia.
Above result shows: the pathological changes of rat bacterial vaginitis in this experiment, mainly show as the cell infiltration that has in the shallow layer tissue under the mucosal epithelium based on mononuclear phagocyte, and mucomembranous epithelial cell does not have degeneration, necrosis.
Cathelicidin-BF is basic identical to colpitic effect and its colpitic result to infection of staphylococcus aureus of coli-infection, it obviously suppresses intravaginal staphylococcus aureus or escherichia coli, and cathelicidin-BF has the effect that significantly reduces inflammation.
SEQUENCE?LISTING
＜110〉Kunming Institute of Zoology, Chinese Academy of Sciences
＜120〉application of Bungarus fasciatus antibacterial peptide cathelicidin-BF
<130> 1
<160> 2
<170> PatentIn?version?3.4
<210> 1
<211> 750
<212> DNA
<213> Bungarus?fasciatus
<400> 1
atggaagggt?tcttctggaa?gaccttgctg?gtggttggag?ctcttgccat?tgctgggacc 60
tcctcacttc?cacacaaacc?cctgatctat?gaagaggctg?tggaccttgc?agtgagcatc 120
tacaacagca?aatctgggga?agactctctc?taccgtctcc?tggaggctgt?ttctccaccc 180
aagtgggatc?ctctttctga?aagcaaccaa?gagctgaact?tcaccatgaa?ggagacggtg 240
tgcctggtgg?ccgaagaacg?atccttggag?gaatgcgact?tccaggaaga?cggggtcgtc 300
atgggatgca?caggctacta?tttcttcggg?gagtcgcccc?cggtggtcgt?tctcacctgc 360
aagcctgtgg?gtgaagaagg?ggagcagaag?caggaggagg?ggaacgagga?ggagaaggaa 420
gtggaggagg?aggaacagga?ggaagacgag?aaggatcagc?ccaggagggt?caagagattc 480
aagaaatttt?tcaggaagct?gaagaagagc?gtgaagaaac?gtgccaagga?attcttcaag 540
aagccgaggg?tcatcggggt?ctccatcccc?ttctaagaga?ggggctcaga?aggacctgcg 600
gcctccgctc?tccgatccca?ggaaaaccgg?cagagaagac?gatgcgggat?gctccagtcc 660
gtcaaatcat?ttcccaatag?gatgctccgc?cattcaatcc?atgaataaat?aaatatatac 720
ttgaaaaaaa?aaaaaaaaaa?aaaaaaaaaa 750
<210> 2
<211> 30
<212> PRT
<213> Bungarus?fasciatus
<400> 2
Lys?Phe?Phe?Arg?Lys?Leu?Lys?Lys?Ser?Val?Lys?Lys?Arg?Ala?Lys?Glu
1 5 10 15
Phe?Phe?Lys?Lys?Pro?Arg?Val?Ile?Gly?Val?Ser?Ile?Pro?Phe
20 25 30
Claims (1)
1. the application of Bungarus fasciatus antibacterial peptide cathelicidin-BF, it is characterized in that the effect that Bungarus fasciatus antibacterial peptide cathelicidin-BF has obvious inhibition, quick sterilization and obviously reduces inflammation staphylococcus aureus and escherichia coli, can be as the application in the preparation treatment bacterial vaginitis medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102650119A CN102294019A (en) | 2011-09-07 | 2011-09-07 | Application of cathelicidin-BF |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102650119A CN102294019A (en) | 2011-09-07 | 2011-09-07 | Application of cathelicidin-BF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102294019A true CN102294019A (en) | 2011-12-28 |
Family
ID=45354851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102650119A Pending CN102294019A (en) | 2011-09-07 | 2011-09-07 | Application of cathelicidin-BF |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102294019A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102702333A (en) * | 2012-05-29 | 2012-10-03 | 中国药科大学 | Drug-resistant pathogen infection resistant polypeptide and uses thereof |
| CN102924574A (en) * | 2012-10-26 | 2013-02-13 | 苏州康尔生物医药有限公司 | Antibacterial peptide LZ1 and application of antibacterial peptide in preparation of antibacterial medicament |
| CN103127493A (en) * | 2013-02-20 | 2013-06-05 | 中国药科大学 | Purpose of polypeptide Cbf-K16 anti-tumor drugs |
| CN103655509A (en) * | 2013-11-26 | 2014-03-26 | 苏州康尔生物医药有限公司 | Effervescent tablet as well as preparation method and application thereof |
| CN104027792A (en) * | 2014-05-16 | 2014-09-10 | 浙江大学 | C-BF (Cathelicidin-BF) protective rat animal model established by LPS (lipopolysaccharide) stimulation |
| EP3255059A4 (en) * | 2015-02-06 | 2017-12-13 | Zhejiang University | Antimicrobial peptide wy-21 and use thereof |
| CN112493312A (en) * | 2020-11-23 | 2021-03-16 | 大连工业大学 | Application and application of antibacterial peptide Cm-CATH2 in prevention and control of Fusarium meyeri in grains |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101386640A (en) * | 2008-09-27 | 2009-03-18 | 中国科学院昆明动物研究所 | Variant cathelicidin-BF15 of cathelicidin-BF and use thereof |
| CN101412753A (en) * | 2008-09-27 | 2009-04-22 | 中国科学院昆明动物研究所 | Bungarus fasciatus antibacterial peptide cathelicidin-BF, and genes and uses thereof |
-
2011
- 2011-09-07 CN CN2011102650119A patent/CN102294019A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101386640A (en) * | 2008-09-27 | 2009-03-18 | 中国科学院昆明动物研究所 | Variant cathelicidin-BF15 of cathelicidin-BF and use thereof |
| CN101412753A (en) * | 2008-09-27 | 2009-04-22 | 中国科学院昆明动物研究所 | Bungarus fasciatus antibacterial peptide cathelicidin-BF, and genes and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| 刘朝晖和董悦: "需氧菌阴道炎菌群及治疗效果的临床研究", 《现代妇产科进展》, vol. 18, no. 11, 30 November 2009 (2009-11-30), pages 832 - 835 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102702333A (en) * | 2012-05-29 | 2012-10-03 | 中国药科大学 | Drug-resistant pathogen infection resistant polypeptide and uses thereof |
| CN102924574A (en) * | 2012-10-26 | 2013-02-13 | 苏州康尔生物医药有限公司 | Antibacterial peptide LZ1 and application of antibacterial peptide in preparation of antibacterial medicament |
| CN103127493A (en) * | 2013-02-20 | 2013-06-05 | 中国药科大学 | Purpose of polypeptide Cbf-K16 anti-tumor drugs |
| CN103127493B (en) * | 2013-02-20 | 2014-10-29 | 中国药科大学 | Purpose of polypeptide Cbf-K16 anti-tumor drugs |
| CN103655509A (en) * | 2013-11-26 | 2014-03-26 | 苏州康尔生物医药有限公司 | Effervescent tablet as well as preparation method and application thereof |
| CN104027792A (en) * | 2014-05-16 | 2014-09-10 | 浙江大学 | C-BF (Cathelicidin-BF) protective rat animal model established by LPS (lipopolysaccharide) stimulation |
| EP3255059A4 (en) * | 2015-02-06 | 2017-12-13 | Zhejiang University | Antimicrobial peptide wy-21 and use thereof |
| CN112493312A (en) * | 2020-11-23 | 2021-03-16 | 大连工业大学 | Application and application of antibacterial peptide Cm-CATH2 in prevention and control of Fusarium meyeri in grains |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102294019A (en) | Application of cathelicidin-BF | |
| Nigam et al. | Maggot therapy: the science and implication for CAM part II—maggots combat infection | |
| CN101829320B (en) | Collagen gel and preparation method thereof | |
| CN101386640A (en) | Variant cathelicidin-BF15 of cathelicidin-BF and use thereof | |
| CN103665111B (en) | Variant HC-15 of a kind of chittue antibacterial peptide Hc-CATH and its preparation method and application | |
| CN107185031B (en) | A kind of biologically active medical dressing and preparation method thereof | |
| CN100475840C (en) | Wasp antibiotic peptide and preparing method and use thereof | |
| CN105111288A (en) | Acinetobacter baumannii subunit vaccine antigen protein, and applications thereof | |
| CN114432276A (en) | Bacterial response microneedle patch and preparation method and application thereof | |
| CN114044812A (en) | Polypeptide for relieving bacterial drug resistance, pharmaceutical composition thereof and application of polypeptide and pharmaceutical composition | |
| CN111518187B (en) | Antibacterial peptide DN6NH2 and application thereof | |
| CN102363040B (en) | Antimicrobial peptide preparation for mucosal tissues | |
| CN101475920B (en) | Preparation method of Bacillus pumilus for treating burn and metabolite | |
| CN104761629A (en) | A broadspectrum efficient antimicrobial peptide Pb-CATH-OH1, a gene thereof, a preparing method of the peptide and applications of the peptide | |
| CN107794232B (en) | Streptococcus antagonizing growth of propionibacterium acnes and gram-positive bacteria and metabolites thereof | |
| CN115581762A (en) | Medical bioprotein repair gel for clearing HPV virus infection and preparation method thereof | |
| CN104840424A (en) | Hypericin albumin nanoparticle and escherichia coli serum antibody compound and preparation method and application thereof | |
| CN107216369A (en) | Similar active peptide of a kind of nucleoprotamine and preparation method and application | |
| CN110917339B (en) | Lysostaphin gel and application thereof in MRSA (tissue-specific respiratory tract infection) wound surface | |
| CN110559423A (en) | Application of thymol in preparation of medicine for treating biofilm infection | |
| CN108721619B (en) | Method for improving killing gram-negative bacteria of aminoglycoside antibiotics by heat shock | |
| CN101642475A (en) | Microbial preparation for preventing and treating mastitis and applications thereof | |
| CN110898123A (en) | Traditional Chinese medicine composition for inhibiting growth of pathogenic microorganisms of animal vaginitis and preparation method and application thereof | |
| CN103655509B (en) | A kind of effervescent tablet, its preparation method and application | |
| CN1161377C (en) | Giant web bombinator skin peptide and its prepn. and pharmaceutical application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111228 |